Pharming is delighted to announce that CEO Sijmen de Vries was the winner of the Chief Executive of the Year Award at the 2023 European Mediscience Awards in London on Thursday evening. Scroll down for the Dutch translation.

Pharming Group N.V. (“Pharming” or “the Company”) (EURONEXT Amsterdam: PHARM/Nasdaq: PHAR) announces that it has entered into a definitive agreement with Novartis Pharma A.G. (“Novartis") to sell its Rare Pediatric Disease Priority Review Voucher (PRV) to Novartis for a pre-agreed, one-time payment of approximately US$21.1 million shortly after closing.

Pharming Group N.V. announces that Pharming’s management will attend the following investor conferences in the month of June:

Pharming Group N.V. (“Pharming” or “the Company”) (Euronext: PHARM/Nasdaq: PHAR) announces that at its Annual General Meeting of Shareholders (AGM) held today, the proposal for a specific authorization for the issuance of shares (or rights to acquire shares) to finance mergers, acquisitions, or strategic alliances, was not put up for a vote. All other proposals were approved.

Pharming Group N.V. presents its preliminary, unaudited financial report for the first quarter ended March 31, 2023.

Pharming Group N.V. announces that Pharming’s Chief Executive Officer, Sijmen de Vries will attend the H.C. Wainwright BioConnect Investor Conference 2023 on May 2, 2023 in New York and will take part in a fireside chat at 11:00 ET/17:00 CEST.

Pharming Group N.V. announces that Pharming’s Chief Executive Officer, Sijmen de Vries and Chief Financial Officer, Jeroen Wakkerman will attend the Van Lanschot Kempen Life Sciences Conference on April 25 and 26, 2023 in Amsterdam, the Netherlands.

Pharming Group N.V. confirms it will announce first quarter 2023 financial results for the month ended March 31, 2023 on Thursday, May 11, 2023.

Pharming Group N.V. announces that Pharming’s management will attend the 22nd Annual Needham Virtual Healthcare Conference April 17 - 20, 2023.

Pharming Group N.V. announces the first commercial shipments of Joenja® (leniolisib) to patients in the United States.